Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Grüneberg RN[au]:

A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Wilson AP et al. Lancet. (1986)

Anti-gram-positive agents. What we have and what we would like. Grüneberg RN et al. Drugs. (1997)

Dosage recommendations for teicoplanin. Wilson AP et al. J Antimicrob Chemother. (1993)

Search results

Items: 1 to 50 of 129

1.

The Alexander Project: the benefits from a decade of surveillance.

Felmingham D, White AR, Jacobs MR, Appelbaum PC, Poupard J, Miller LA, Grüneberg RN.

J Antimicrob Chemother. 2005 Oct;56 Suppl 2:ii3-ii21.

PMID:
16282278
2.

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; Alexander Project Group.

J Antimicrob Chemother. 2003 Aug;52(2):229-46. Epub 2003 Jul 15.

PMID:
12865398
3.

Global surveillance through PROTEKT: the first year.

Grüneberg RN.

J Chemother. 2002 Jul;14 Suppl 3:9-16.

PMID:
12418556
5.

The role of glycopeptide antibiotics in the treatment of infective endocarditis.

Grüneberg RN, Antunes F, Chambers HF, Garau J, Graninger W, Menichetti F, Peetermans WE, Pittet D, Shah PM, Vogelaers D.

Int J Antimicrob Agents. 1999 Aug;12(3):191-8. Review.

PMID:
10461836
6.

Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996.

Butler DL, Gagnon RC, Miller LA, Poupard JA, Felmingham D, Grüneberg RN.

J Antimicrob Chemother. 1999 Jun;43(6):777-82.

PMID:
10404316
7.

Chairman's introduction--the importance of good quality surveillance data today.

Grüneberg RN.

J Chemother. 1999 Feb;11 Suppl 1:22-5.

PMID:
10207770
8.
9.

The role of antibiotics in the treatment of chronic prostatitis: a consensus statement.

Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, Palou Redorta J, van Cangh PJ.

Eur Urol. 1998 Dec;34(6):457-66. Review.

PMID:
9831786
10.

The Nearchus project: antibiotic susceptibility of respiratory pathogens and clinical outcome in lower respiratory tract infections at 27 centres in the UK.

Grüneberg RN, Felmingham D, Harding I, Shrimpton SB, Nathwani A.

Int J Antimicrob Agents. 1998 May;10(2):127-33.

PMID:
9716289
11.

Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season.

Felmingham D, Robbins MJ, Tesfaslasie Y, Harding I, Shrimpton S, Grüneberg RN.

J Antimicrob Chemother. 1998 Mar;41(3):411-5.

PMID:
9578171
12.

Empirical antibacterial treatment for sepsis and the role of glycopeptides: recommendations from a European panel.

Pittet D, Menichetti F, Antunes F, Garau J, Graninger W, Grüneberg RN, Peetermans WE, Shah PM.

Clin Microbiol Infect. 1997 Jun;3(3):273-282. No abstract available.

13.

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.

Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.

J Antimicrob Chemother. 1997 Jun;39 Suppl B:43-9.

PMID:
9222069
14.

Anti-gram-positive agents. What we have and what we would like.

Grüneberg RN.

Drugs. 1997;54 Suppl 6:29-38. Review.

PMID:
9474479
15.

Antimicrobial susceptibility of community-acquired bacterial lower respiratory tract pathogens.

Felmingham D, Robbins MJ, Dencer C, Nathwani A, Grüneberg RN.

J Antimicrob Chemother. 1996 Oct;38(4):747-51. No abstract available.

PMID:
8937975
17.

The Alexander Project: using in-vitro susceptibility data for choosing empirical therapy in LRTI.

Grüneberg RN.

J Antimicrob Chemother. 1996 Jul;38 Suppl A:155-70.

PMID:
8858481
20.

Anti-infective treatment in intensive care: the role of glycopeptides.

Grüneberg RN, Wilson AP.

Intensive Care Med. 1994 Nov;20 Suppl 4:S17-22. Review.

PMID:
7699151
21.

Use of teicoplanin in community medicine.

Wilson AP, Grüneberg RN.

Eur J Clin Microbiol Infect Dis. 1994 Sep;13(9):701-10. Review.

PMID:
7843174
22.

Changes in urinary pathogens and their antibiotic sensitivities, 1971-1992.

Grüneberg RN.

J Antimicrob Chemother. 1994 May;33 Suppl A:1-8.

PMID:
7928827
23.

A critical review of the dosage of teicoplanin in Europe and the USA.

Wilson AP, Grüneberg RN, Neu H.

Int J Antimicrob Agents. 1994 Apr;4 Suppl 1:1-30.

PMID:
18611626
24.

An in vitro characterization of cefditoren, a new oral cephalosporin.

Felmingham D, Robbins MJ, Ghosh G, Bhogal H, Mehta MD, Leakey A, Clark S, Dencer CA, Ridgway GL, Grüneberg RN.

Drugs Exp Clin Res. 1994;20(4):127-47.

PMID:
7813385
25.

Dosage recommendations for teicoplanin.

Wilson AP, Grüneberg RN, Neu H.

J Antimicrob Chemother. 1993 Dec;32(6):792-6. Review. No abstract available.

PMID:
8144419
26.

Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992.

Neu HC, Wilson AP, Grüneberg RN.

J Chemother. 1993 Apr;5(2):67-93. Review.

PMID:
8515298
27.

Audit of prescription and assay of aminoglycosides in a UK teaching hospital.

Shrimpton SB, Milmoe M, Wilson AP, Felmingham D, Drayan S, Barrass C, Grüneberg RN, Ridgway GL.

J Antimicrob Chemother. 1993 Apr;31(4):599-606.

PMID:
8514654
28.

Roundtable discussion. Maximizing potential cost benefits of teicoplanin through appropriate usage.

Rybak MJ, Allen R, Arnow P, Craven PC, Freeman R, Grüneberg RN, Korin J, Nightingale CH, Rubinstein E, Schaison GS, et al.

Hosp Formul. 1993 Jan;28 Suppl 1:62-8. No abstract available.

PMID:
10123844
29.

The true cost of monitoring antibiotic levels.

Grüneberg RN.

Hosp Formul. 1993 Jan;28 Suppl 1:55-8.

PMID:
10123841
30.

Enterococcus species in urinary tract infection.

Felmingham D, Wilson AP, Quintana AI, Grüneberg RN.

Clin Infect Dis. 1992 Aug;15(2):295-301.

PMID:
1387807
31.
32.

Interference of cefpirome with the measurement of plasma creatinine.

Kulkarni S, Wilson AP, Grüneberg RN, Filipiak C, Samuell CT.

J Antimicrob Chemother. 1991 Oct;28(4):617-9. No abstract available.

PMID:
1761460
33.

Changes in the antibiotic sensitivities of urinary pathogens, 1971-1989.

Grüneberg RN.

J Antimicrob Chemother. 1990 Dec;26 Suppl F:3-11.

PMID:
2292543
34.

Routine screening for Corynebacterium diphtheriae.

Wilson AP, Ridgway GL, Grüneberg RN, Efstratiou A, Colman G, Cookson B.

Lancet. 1990 Nov 10;336(8724):1199. No abstract available.

PMID:
1978064
35.

In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.

O'Hare MD, Ghosh G, Felmingham D, Grüneberg RN.

J Antimicrob Chemother. 1990 Feb;25(2):217-20.

PMID:
2139436
36.

Resistance studies with ofloxacin.

Foxall PA, Felmingham D, Grüneberg RN.

J Chemother. 1989 Jul;1(4 Suppl):381-3. No abstract available.

PMID:
16312450
37.

In vitro bactericidal activity of the glycopeptide compounds vancomycin, teicoplanin and ramoplanin (A-16686/MDL 62,198).

O'Hare MD, Felmingham D, Grüneberg RN.

J Chemother. 1989 Jul;1(4 Suppl):210-1. No abstract available.

PMID:
16312373
38.

In vitro activity and synergy studies with fleroxacin.

Felmingham D, Robbins MJ, O'Hare MD, Jones K, Ridgway G, Grüneberg RN.

J Chemother. 1989 Jul;1(4 Suppl):162-4. No abstract available.

PMID:
16312352
39.

Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.

Robbins MJ, Baskerville AJ, Sanghrajka M, Mumtaz G, Felmingham D, Ridgway GL, Grüneberg RN.

Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):65S-76S.

PMID:
2791500
40.

The bactericidal activity of vancomycin and teicoplanin against methicillin-resistant strains of coagulase negative Staphylococcus spp.

O'Hare MD, Felmingham D, Grüneberg RN.

J Antimicrob Chemother. 1989 May;23(5):800-2. No abstract available.

PMID:
2527220
41.

Serum and tissue levels of teicoplanin during cardiac surgery: the effect of a high dose regimen.

Wilson AP, Shankar S, Felmingham D, Treasure T, Grüneberg RN.

J Antimicrob Chemother. 1989 Apr;23(4):613-7.

PMID:
2526112
42.

Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.

Felmingham D, Robbins MJ, Baskerville AJ, Sanghrajka MD, Ridgway GL, Grüneberg RN.

Drugs Exp Clin Res. 1989;15(2):59-62.

PMID:
2737080
43.

Should the temperature chart influence management in cardiac operations? Result of a prospective study in 314 patients.

Wilson AP, Treasure T, Grüneberg RN, Sturridge MF, Burridge J.

J Thorac Cardiovasc Surg. 1988 Oct;96(4):518-23.

PMID:
3050285
44.

Teicoplanin revisited.

Williams AH, Grüneberg RN.

J Antimicrob Chemother. 1988 Oct;22(4):397-401. No abstract available.

PMID:
2974450
45.

The comparative in-vitro activity of ofloxacin.

Grüneberg RN, Felmingham D, O'Hare MD, Robbins MJ, Perry K, Wall RA, Ridgway GL.

J Antimicrob Chemother. 1988 Sep;22 Suppl C:9-19.

PMID:
3182468
46.

Resistance studies with ofloxacin.

Felmingham D, Foxall P, O'Hare MD, Webb G, Ghosh G, Grüneberg RN.

J Antimicrob Chemother. 1988 Sep;22 Suppl C:27-34.

PMID:
3182460
47.

Minimum effective dose of trimethoprim for urinary tract infection.

Blackstone V, Grüneberg RN.

J R Coll Gen Pract. 1988 Jul;38(312):320.

48.

Assessment of a new test ("Staphylase') for the identification of Staphylococcus aureus.

Cremer AW, Grüneberg RN.

Med Lab Sci. 1988 Jul;45(3):221-4. No abstract available.

PMID:
3210927
49.

Contamination of blood during cardiopulmonary bypass: the effect of antibiotic prophylaxis.

Wilson AP, Felmingham D, Grüneberg RN, Treasure T, Sturridge MF.

J Hosp Infect. 1988 Jul;12(1):35-42.

PMID:
2905372
50.

Supplemental Content

Loading ...
Support Center